化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化*

doi:10.3969/j.issn.1672-5069.2020.01.037

摘要/Abstract

摘要： 目的通过分析化浊通瘀汤干预非酒精性脂肪性肝病(NAFLD)大鼠血清肿瘤坏死因子-α(TNF-α)和瘦素(leptin)水平变化,揭示化浊通瘀汤防治NAFLD的机制。方法将60只SD大鼠随机分为对照组12只和模型组48只,给予高脂饲料建立NAFLD模型,再将模型动物随机分为模型组、大中小化浊通瘀汤处理组和水飞蓟宾处理组,分别给予不同的药物灌胃8 w。采用ELISA法检测血清TNF-α和leptin水平。结果大、中、小剂量化浊通瘀汤处理组大鼠体质量分别为(566±19.4)g、(577±24.3)g、(585±18.5)g,显著低于模型组;大、中、小剂量化浊通瘀汤处理组血清TNF-α水平分别为(30.7±3.5)pg/mL、(34.1±4.2)pg/mL、(37.0±2.3)pg/mL,显著低于模型组;大、中剂量化浊通瘀汤处理组血清瘦素水平分别为(2.8±0.2)ng/mL和(2.8±0.1)ng//mL,显著低于模型组;与模型组相比,各中药干预组血清AST、ALT、TG、TC、FBG水平均显著下降 (P<0.01)。结论化浊通瘀汤干预能减轻NAFLD动物肝组织炎症,降低血清TNF-α和瘦素水平。

关键词: 非酒精性脂肪性肝病, 化浊通瘀汤, 肿瘤坏死因子, 瘦素

Abstract: Objective To explore the mechanism of traditional Chinese medicine in the prevention and treatment of non-alcoholic fatty liver disease (NAFLD) by detecting serum tumor necrosis factor (TNF)-α and leptin in SD rat models with NAFLD. Methods 60 rats were randomly divided into normal (n=8) and high-fat-feeding group (n=48). Three rats were selected for tissue biopsies in the two groups after 10 weeks experiments. The model rats were further divided into model, three doses of herbal medicine and silybinbin-intervened group for eight weeks. Serum TNF-α and leptin levels were detected by ELISA. Results The body weights in low-, middle- and high dose of herbal medicine were were(566±19.4)g, (577±24.3)g and (585±18.5)g, significantly less than in the model group; serum TNF-α levels in three herbal medicine-intervend groups were (30.7±3.5)pg/mL, (34.1±4.2)pg/mL and (37.0±2.3)pg/mL, respectively, much lower than in the model; serum leptin levels in large- and middle-dose-intervined groups were (2.8±0.2)ng/mL and (2.8±0.1)ng//mL, significantly lower than in the model; serum AST, ALT, TG, TC and festing blood glucose levels in three herbal medicine-intervened groups decreased obviously as compared to those in the model (P<0.01). Conclusion The Chinese herbal medicine might ameliorate liver steatosis by down-regulation of TNF-α and leptin in rats with NAFLD, which warrants further investigation.

Key words: Non-alcoholic fatty liver diseases, Herbal medicine, Tumor necrosis factor-α, Leptin

郭化磊, 卜理琳, 裴颖, 殷宏振, 黄峰. 化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化^*[J]. 实用肝脏病杂志, 2020, 23(1): 138-141.

Guo Hualei, Bu Lilin, Pei Ying, et al. Effect of Chinese herbal medicine on serum TNF-α and leptin levels in rats with NAFLD[J]. Journal of Practical Hepatology, 2020, 23(1): 138-141.

参考文献

[1] La Brecque DR, Abbas Z, Anaia F, et al. World Gastroenterology Organisation global guidelines:Nonalcoholic fatty? nonalcoholic steatohepatitis. J Clin Gastroenterol,2014,48(6):467–473.
[2] Qu LL,Yu B,Li Z,et al. Gastrodin ameliorates oxidative stress and proinflammatory response in nonalcoholic fatty liver disease through the AMPK/Nrf2 pathway. Phytother Res,2016,30(3):402.
[3] Lonardo A,Nascimbeni F,Mauratonio M,et al.Nonalcoholic fatty liver disease: evolving paradigms.World J Gastroenterol,2017,23(36):6571-6592.
[4] Pimpin L,Cortez-Pinto H,Negro F,et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol,2018,69(3):718-735.
[5] Friedman SL,Neuschwnder Tetri BA, Rinella M,et al. Mechanisms of NAFLD development and therapeutic strategies.Nat Med,2018,24(7):908-922.
[6] Wu J, Xu H, Wang C, et al. The 6-year changes of epidemiology of non-alcoholic fatty liver diseaseamong general population of northeastern in China. Hepatol Int, 2017 (11):S562.
[7] Pervez M A, Khan D A, Ijaz A,et al. Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease. Turk J Gastroenterol,2018,29(2):170-176.
[8] 邴浩,李异玲.NAFLD与肝细胞癌的相关性研究进展.实用肝脏病杂志,2018,21(5):821-824.
[9] Mouzaki M,Wang A Y,Bandsma R,et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. Plos One,2016,11(5):1829-1830.
[10] Townsend SA, Newsome PN. Non-alcoholic fatty liver disease in 2016.Br Med Bull,2016,119(1):143-156.
[11] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD).Metabolism,2016,65(8):1038-1048.
[12] 杨惠敏,蒋春彦.自拟中药方剂联合水飞蓟宾治疗非酒精性脂肪性肝病患者临床疗效研究. 实用肝脏病杂志,2018,21(3):467-468.
[13] Gong XW, Han L,Yang QH,et al. Effects ofsoothing liver and invigorating spleen recipe on lipid metabolism disorders in kupffer cells of NAFLD rats by LXRa/SREBP-1c signal pathway. Chin Herbal Med,2014,6(4):297-304.
[14] Ceccarelli S,Panera N, Mina M,et al.LPS-induced TNF-αfactor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.Oncotarget,2015,6(39):41434-41452.
[15] Purnomo HD, Mundhofir FE, Kasno G, et al.Combination of aspartate aminotranferase and tumor necrosis factor-αas non invasive diagnostic tools for non alcoholic steatohepatitis(NASH).Acta Med Indones, 2015, 47(1):16-23.
[16] Polyzos S A,Kountouras J,Zavos C.Nonalcoholic fatty liver disease:the pathogenetic roles of insulin resistance and adipocytokines.Curr Mol Med,2009, 9(3):299-314.
[17] Alhasson F,Seth R K,Sarkar S,et al.High circulatory leptin mediated NOX-2-peroxynitrite-mi R21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease.Redox Biol,2018, 17:1-15.
[18] Rosso N,Marin V,Giordani A,et al.The pros and the cons for the use of silybin-rich oral formulations in treatment of liver damage(NAFLD in particular).Curr Med Chem,2015,22(25):2954-2971.
[19] Polimeni L,Del Ben M,Baratta F,et al.Oxidative stress:new insights on the association of non-alcoholicfatty liver disease and atherosclerosis.World J Hepatol, 2015,7(10):1325-1336.
[20] 郭一,李军祥,毛堂友,等.自噬相关蛋白在高脂饲料诱导的非酒精性脂肪性肝炎大鼠肝脏中的表达及茵陈苓桂术甘汤的干预效应.中华中医药学刊,2018,36(4):789-801.
[21] Xie Y,Miranda SR,Hoskins JM,et al.Role of UDP-glucuronosyltransferase1A1 in the metabolism and pharmacokinetics of silymarin flavonolignans in patients with HCV and NAFLD.Molecules,2017,22(1):e142.
[22] 解占峰,贾继珍,赵淑芳.三七总皂苷联合水飞蓟宾治疗非酒精性脂肪性肝病患者疗效及其对血清细胞因子水平的影响.实用肝脏病杂志,2018,21(4):623-624.

化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化^*

Effect of Chinese herbal medicine on serum TNF-α and leptin levels in rats with NAFLD

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈丽丽, 符茂雄, 蒙绪标, 方其超. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 38-41.
[2]	柳健, 朱峰发, 唐娟. 非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*[J]. 实用肝脏病杂志, 2020, 23(1): 42-45.
[3]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[4]	毛重山, 殷辉, 肖二辉, 张英英. 非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 50-53.
[5]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.
[6]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[7]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[8]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[9]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[10]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[11]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[12]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[13]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[14]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[15]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.